UnknownNCT03781752

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Medication studyAges 6–17United States

The study in practice

Understand this study

This study is for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria apply.

Listed locations: Gainesville, United States · New York, United States and 2 more locationsSee all locations and recruitment
Activities: Medication described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: March 4, 2018

Recruitment status: Unknown
Enrollment listed in the registry: 500
Sponsor: Icahn School of Medicine at Mount Sinai
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: United States
Age range: From 6 Years to 17 Years
Official registry ID: NCT03781752
Official title: Show the full official title
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Status unknown

Gainesville · New York · Cincinnati

1 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Icahn School of Medicine at Mount Sinai, a university.

Does this study involve medication?

Yes. The study involves medication, including Methylphenidate.

Who can participate?

This study is for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria apply.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.